苯磺酸氨氯地平联合心可舒治疗高血压的临床观察
x
请在关注微信后,向客服人员索取文件
篇名: | 苯磺酸氨氯地平联合心可舒治疗高血压的临床观察 |
TITLE: | |
摘要: | 目的:观察苯磺酸氨氯地平联合心可舒治疗高血压的疗效和安全性。方法:100例高血压患者随机分为对照组(50例)和观察组(50例)。对照组患者给予苯磺酸氨氯地平片1片,口服,每日1次; 观察组患者在对照组治疗的基础上给予心可舒片4片,口服,每日3次。两组疗程均为8周。观察两组患者的临床疗效,治疗前后收缩压(SBP)、舒张压(DBP)及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,不良反应发生率显著低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组患者SBP、DBP比较,差异均无统计学意义(P>0.05)。治疗后,两组患者SBP、DBP均显著低于同组治疗前,差异均有统计学意义(P<0.05),但两组比较差异无统计学意义(P>0.05)。结论: 苯磺酸氨氯地平联合心可舒治疗高血压的疗效显著优于单用苯磺酸氨氯地平,且安全性较好。 |
ABSTRACT: | OBJECTIVE: To observe the efficacy and safety of amlodipine besylate combined with Xinkeshu in the treatment of hypertension. METHODS: 100 patients with hypertension were randomly divided into control group (50 cases) and observation group(50 cases). Control group was orally given one Amlodipine besylate tablet, once a day; observation group was additionally given 4 Xinkeshu tablets, 3 times a day. The treatment course was 8 weeks. Clinical efficacy, systolic blood pressure (SBP) and diastolic blood pressure (DBP) before and after treatment in 2 groups were observed, the incidence of adverse reactions was recorded. RESULTS: The total effective rate in observation group was significantly higher than control group, the incidence of adverse reactions was significantly lower than control group, the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in the SBP and DBP between 2 groups (P>0.05). After treatment, the SBP and DBP in 2 groups were significantly lower than before, the differences were statistically significant (P<0.05); but there was no significant difference between 2 groups (P>0.05). CONCLUSIONS: The efficacy of amlodipine besylate combined with Xinkeshu is superior to amlodipine besylate alone in the treatment of hypertension, with better safety. |
期刊: | 2016年第27卷第15期 |
作者: | 陈刚,宋敏,孙小东 |
AUTHORS: | CHEN Gang,SONG Min,SUN Xiaodong |
关键字: | 苯磺酸氨氯地平;心可舒;高血压;疗效;安全性 |
KEYWORDS: | Amlodipine besylate; Xinkeshu; Hypertension; Efficacy; Safety |
阅读数: | 927 次 |
本月下载数: | 5 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!